Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Uro
Special Issues
Prostate Cancer and Erectile Disfunction
share announcement

Prostate Cancer and Erectile Disfunction

A special issue of Uro (ISSN 2673-4397).

Deadline for manuscript submissions: closed (15 May 2024) | Viewed by 14240

Special Issue Editor

Dr. Alessandro Tafuri

E-Mail Website
Guest Editor
Department of Urology, Vito Fazzi Hospital, Lecce, Italy
Interests: urothelial cancer; translational research; minimal invasive surgery; robotic surgery

Special Issue Information

Dear Colleagues,

Prostate cancer (PCa) is the second most common cancer in males, and it represents the first cause of cancer death for cancer in this population. In the last few years, the incidence of PCa in young men has been increasing as a result of several factors, and this has an important impact on sexual function and quality of life. It is known that PCa treatments such as radical prostatectomy, radiotherapy, and castration therapy impact sexual function with different action mechanisms. However, the psychological distress related to cancer diagnosis, and specifically prostate cancer diagnosis, might add a particular burden on erectile function in a subset of patients that may already have some initial erectile difficulty due to the aging further compromising quality of life. Here I would like to investigate with mini-reviews the state of the art of the following related topics:

  • Prostate cancer diagnosis and psychological distress: impact on erectile function;
  • Radical prostatectomy and minimally invasive prostate cancer treatment: impact on erectile function;
  • Radiotherapy and hormonal treatment: impact on erectile function;
  • Rehabilitation after prostate cancer treatment: which is the right program?
  • New sexual rehabilitation tools after prostate cancer treatments: an overview.

Dr. Alessandro Tafuri
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Uro is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • prostate cancer
  • prostate cancer treatment
  • radiotherapy
  • castration therapy
  • radical prostatectomy
  • erectile disfunction

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

13 pages, 610 KiB  
Review
Current Knowledge on Radiation-Therapy-Induced Erectile Dysfunction in Prostate-Cancer Patients: A Narrative Review
by Connie Labate, Andrea Panunzio, Francesco De Carlo, Federico Zacheo, Sara De Matteis, Maria Cristina Barba, Umberto Carbonara, Floriana Luigina Rizzo, Silvana Leo, Saverio Forte, Pasquale Ditonno, Alessandro Tafuri and Vincenzo Pagliarulo
Uro 2023, 3(2), 104-116; https://doi.org/10.3390/uro3020013 - 1 Apr 2023
Cited by 1 | Viewed by 4731
Abstract
Prostate cancer is the most frequently diagnosed cancer in men in the United States. Among the different available treatment options, radiation therapy is recommended for localized or even advanced disease. Erectile dysfunction (ED) often occurs after radiation therapy due to neurological, vascular, and [...] Read more.
Prostate cancer is the most frequently diagnosed cancer in men in the United States. Among the different available treatment options, radiation therapy is recommended for localized or even advanced disease. Erectile dysfunction (ED) often occurs after radiation therapy due to neurological, vascular, and endocrine mechanisms resulting in arterial tone alteration, pudendal-nerve neuropraxia, and lastly fibrosis. Considering the influence of quality of life on patients’ treatment choice, radiation-therapy-induced ED prevention and treatment are major issues. In this narrative review, we briefly summarize and discuss the current state of the art on radiation-therapy-induced ED in PCa patients in terms of pathophysiology and available treatment options. Full article
(This article belongs to the Special Issue Prostate Cancer and Erectile Disfunction)
►▼ Show Figures

Figure 1

13 pages, 293 KiB  
Review
Penile Rehabilitation after Prostate Cancer Treatment: Which Is the Right Program?
by Roberto Castellucci, Piergustavo De Francesco, Antonio De Palma, Davide Ciavarella, Simone Ferretti, Michele Marchioni and Luigi Schips
Uro 2023, 3(1), 61-73; https://doi.org/10.3390/uro3010009 - 23 Feb 2023
Cited by 1 | Viewed by 4505
Abstract
The management of sexual complications after treatment of localized prostate cancer, such as erectile dysfunction, changes in the length of the penis, pain during sexual intercourse, and lack of orgasm, is still an unsolved problem with an important impact on patients’ quality of [...] Read more.
The management of sexual complications after treatment of localized prostate cancer, such as erectile dysfunction, changes in the length of the penis, pain during sexual intercourse, and lack of orgasm, is still an unsolved problem with an important impact on patients’ quality of life. In this review, we summarize the current scientific literature about the rehabilitation of erectile dysfunction after prostate cancer treatment. The therapy for penile rehabilitation includes different types of treatments: the combination of phosphodiesterase type 5 inhibitors (PDE5-I) and the vacuum erectile device (VED) are considered first-line treatment options. When therapy begins, the duration of treatment, the dosage and the drug used all play very important roles in the treatment outcome. Intracavernous injection (ICI) therapy represents the second-line option for patients ineligible for PDE5-I therapy. Technological development has led to the emergence of devices for the stimulation of the penis without the use of drugs, such as penile vibratory stimulation (PVS) for stimulation of ejaculation in spinal cord injury and low-intensity extracorporeal shockwave therapy (LIESWT). The rapid diffusion of the latter, thanks to its easy use, attains good results without side effects. The panorama of penile rehabilitation after PC treatments is vast and many studies are needed, especially on new technologies, to find the best therapeutic regimen possible, personalized to the patient’s characteristics and the type of treatment for PC. Full article
(This article belongs to the Special Issue Prostate Cancer and Erectile Disfunction)
9 pages, 240 KiB  
Review
Focal Therapy for Prostate Cancer: The Impact on Sexual Function
by Lorenzo Storino Ramacciotti, Donya S. Jadvar, Maria Sarah L. Lenon, Giovanni E. Cacciamani, Andre Luis Abreu and Masatomo Kaneko
Uro 2022, 2(4), 204-212; https://doi.org/10.3390/uro2040025 - 9 Oct 2022
Cited by 1 | Viewed by 3764
Abstract
Focal therapy (FT) has emerged as a potential treatment for localized prostate cancer (PCa) with encouraging functional outcomes. According to the compelling evidence based on meta-analyses and recent trials, erectile function (EF) is mostly retained at 6 and 12 months after FT when [...] Read more.
Focal therapy (FT) has emerged as a potential treatment for localized prostate cancer (PCa) with encouraging functional outcomes. According to the compelling evidence based on meta-analyses and recent trials, erectile function (EF) is mostly retained at 6 and 12 months after FT when compared to baseline. These findings are consistent across different energy sources reported to date. However, overall, quality of life, including impotence, was not the endpoint for most studies. Additionally, impotency has not been consistently reported in most of the recent literature. Furthermore, confounding factors such as baseline potency and usage of phosphodiesterase 5 inhibitors (PDE5-I) were also frequently undisclosed. Long-term functional outcomes are awaited. To fully comprehend how FT affects EF, more extensive long-term randomized clinical trials using EF as a primary outcome are needed. Full article
(This article belongs to the Special Issue Prostate Cancer and Erectile Disfunction)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop